1. Home
  2. > Pharmaceutical
  3. > Drug Development Market Trends
In Silico Clinical Trials Market- Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

In Silico Clinical Trials Market- Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • August 2022
  • 132 pages
  • ID: 6316193
  • Format: PDF
  • Mordor Intelligence LLP

Summary

Table of Contents

Search Inside

The in silico clinical trials market is expected to register a CAGR of 7.75% over the forecast period 2022-2027.

The unanticipated spread of COVID-19 has a significant influence on the in silico clinical trials market. Even though the news article “Why 2020 Saw The Steady Rise Of In Silico Trials”, published in January 2021, explains that as COVID-19-related constraints continue to cause chaos in the clinical research environment, big pharma companies are increasingly turning to in silico or virtual clinical trials to help companies continue their product development efforts. Before evaluating their drug prospects in humans, companies can use advanced computational modelling and simulation tools to test them in "virtual patients."Additionally, since the in silico studies are based on computer simulations, they are unaffected by the ongoing COVID-19-related travel and social distancing restrictions that have hampered many traditional trials.

Further, the proper understanding of drug efficacy and safety, the growing prevalence of numerous diseases, and the cost-effectiveness of in silico clinical trials make the in silico marketgrow. The article “In silico imaging clinical trials: cheaper, faster, better, safer, and more scalable” published in the Trial journal in 2021, reveals the tremendous advantages offered by in silico clinical trials such as adjustable variability, unlimited samples, no patient risk, and less burden. These advantages in turn lead to the point of high demand for in silico clinical trial market.

Furthermore, market players are engaged in marketing tactics such as mergers and acquisitions, as well as product launches for instance in July 2021, Kiromic Biopharma, Inc., a pioneer in Immuno oncology cellular therapy for solid tumors, has acquired InSilico Solutions. Kiromic will integrate a team of bioinformatics and AI professionals in-house as part of this deal, extending its lead in the race for AI technology that can identify the best biomarkers for cutting-edge immunotherapeutics like CAR-T cell treatment.

Increased understanding of the benefits of insilico clinical trial leads the market to develop exponentially over the ages. The webcast published by United States Food and Drug Administration under the title “ The VICTRE trial: an in-silico replica of a clinical trial for evaluating digital breast tomosynthesis as a replacement for full-field digital mammography” on March 2021, explains the simulated Virtual Imaging Clinical Trial for Regulatory Evaluation (VICTRE trial) compared digital mammography and digital breast tomosynthesis using computer-simulated imaging of 2,986 in silico patients (an advanced type of mammography that generates three-dimensional images of the breasts using a low-dose x-ray system and computer reconstructions). For all breast sizes and lesion types, it showed an improved lesion detection performance favoring tomosynthesis. The improved tomosynthesis performance was in line with findings from a comparison trial including real patients and radiologists.

As a result of the reasons outlined, the explored market is anticipated to grow throughout the analysis period. However, since human subjects are not involved, the results are based on approximation which can restrain in silico clinical trials market growth.

Key Market Trends

Oncology Therapeutic Area is Expected to Witness a Significant Growth Over the Forecast Period

Regular cancer clinical trials are mostly at a high cost, and they also have a significant risk of causing harm to patients. The demand for cancer in silico clinical trials is mostly driven by these considerations. Also, technological advancements such as the use of Artificial Intelligence (AI) in cancer computer simulation studies to improve medication knowledge, safety, and efficacy are boosting the growth of the market.

As per the news published in In silico Medicine in 2022, announces they had completed experimental validation of AI-designed compounds with the requisite features and have nominated a preclinical candidate (PCC) for anti-cancer therapeutics targeting ubiquitin-specific protease 1 (USP1), a known synthetic lethality target. Synthetic lethality, a well-established genetic technique to exploit vulnerabilities in tumor cells to trigger tumor cell death while sparing normal cells, is a potential field of cancer therapy. When used against a wide spectrum of tumor lineages, Insilico’s preclinical candidate molecule showed promising results. In vitro studies revealed that the chemical has a substantial antiproliferative effect in breast cancer gene mutant (BRCA) tumor cells with high selectivity.

The article published in MedRxiv journal under the heading “In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome” in 2021, explains the advantages of cancer immunotherapy coupled with in silico trials. In the study they point out that, for immuno-oncology, in silico studies have major implications such as they offer a cost-effective way to check the validity of the biological assumptions that underpin immunotherapy trials and aid in their design. Along with that, it can be used as a teaching tool that can help scientists in training understand design principles, resulting in better designs and higher success rates in future immunotherapy studies.

As a result of the stated factors, the oncology therapeutic area segment is predicted to develop significantly throughout the forecast period.

North America is Expected to Grow the In Silico Clinical Trials Market

North America had the majority of share in the in silico clinical trials market in 2021. The emergence of this region can be attributed to an increase in understanding of the benefits of in silico trials and reduced side effects that have been raised from human trials.

Key product releases, cost-effectiveness, and the presence of manufacturers in the country are all factors that have contributed to the growth of the in silico clinical trials market. According to the press release on May 2021, Massachusetts-based GNS Healthcare, an artificial intelligence organization that produces in silico patients that simulate therapeutic intervention on a patient-by-patient basis announced that they are planning to develop and launch Gemini, which is an in silico Patient for Prostate Cancer. This in silico patient was created in collaboration with Tempus and is powered by a clinico-genomic data, including whole-exome sequencing (tumor/normal match), RNAseq, patient treatment history, current treatments like Enzalutamide, Abiraterone, Docetaxel, Cabazitaxel, Sipuleucel-T, and Pembrolizumab, as well as related lines of treatment and mortality.

Moreover, according to the report published by the United States Food and Drug Administration on January 2022, describe that In silico clinical trials employing Computational Modeling and Simulation (CM&S), in which a device is evaluated on a cohort of virtual patients, are encouraged by the United States Food and Drug Administration and are expected to replace or augment clinical studies. However, the use of Computational Modeling and Simulation to support regulatory filings is now hampered by a lack of or contradictory information on their reliability. The analyzed market is predicted to grow in the North American region as a result of the aforementioned factors.

Competitive Landscape

The In silico clinical trial market is moderately competitive and consists of several major players. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known. Include Novadiscovery, Insilico Medicine, Inc., GNS Healthcare, InSilicoTrials Technologies, and Immunetrics Inc. among others.

Additional Benefits:

The market estimate (ME) sheet in Excel format
3 months of analyst support

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global miRNA Tools and Services Market Size, Share & Industry Trends Analysis Report By Technology, By End User, By Product & Services, By Regional Outlook and Forecast, 2022 - 2028

  • $ 3600
  • October 2022
  • 218 pages

The Global miRNA Tools and Services Market size is expected to reach $939.8 million by 2028, rising at a market growth of 17.8% CAGR during the forecast period. miRNA is a non-coding and small gene that ...

  • World
  • North America
  • Drug Development
  • Pharmaceutical
  • Industry analysis
  • Chronic Disease Prevalence
  • Cancer Incidence

ref:plp2022

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on